Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...
Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
The uninsured rate has been cut in half, but Americans are sicker, and their life expectancy is stagnating. Doing more of the ...
As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...
In recent years, more and more celebrities — like Elon Musk and Whoopi Goldberg — have spoken up about using GLP-1 ...
In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback